| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 6,571 | 4,737 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 216 | 220 |
| Net decrease in cash, cash equivalents and restricted cash | -5,377 | -3,579 |
| Cash and cash equivalents at beginning of period | 46,354 | - |
| Cash and cash equivalents at end of period | 40,977 | - |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)